Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
May 27, 2024
- Pharmaceuticals
- R&D
Verastem Oncology Announces Updates on Avutometinib Development
TOKYO, May 27, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Verastem Oncology (Nasdaq: VSTM) issued a press release on May 24 that Verastem Oncology has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the combination of avutometinib, a RAF/MEK inhibitor, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer, who received at least one prior systemic therapy. Avutometinib was created by Chugai, and its clinical development is being conducted by Verastem Oncology.
Please refer to the link below for details of the Verastem Oncology’s press release:
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-initiation-rolling-submission-nda
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
